Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Oakworth Capital Inc.

Oakworth Capital Inc. lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,006 shares of the biopharmaceutical company’s stock after selling 300 shares during the period. Oakworth Capital Inc.’s holdings in Gilead Sciences were worth $370,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in GILD. Algert Global LLC acquired a new stake in shares of Gilead Sciences during the 2nd quarter worth about $254,000. AMF Tjanstepension AB raised its position in shares of Gilead Sciences by 14.7% during the 3rd quarter. AMF Tjanstepension AB now owns 400,819 shares of the biopharmaceutical company’s stock worth $33,645,000 after acquiring an additional 51,390 shares in the last quarter. Czech National Bank raised its position in shares of Gilead Sciences by 6.8% during the 3rd quarter. Czech National Bank now owns 253,618 shares of the biopharmaceutical company’s stock worth $21,263,000 after acquiring an additional 16,209 shares in the last quarter. Aprio Wealth Management LLC purchased a new position in Gilead Sciences during the 3rd quarter worth approximately $290,000. Finally, Atomi Financial Group Inc. grew its stake in Gilead Sciences by 36.0% during the 3rd quarter. Atomi Financial Group Inc. now owns 6,081 shares of the biopharmaceutical company’s stock worth $510,000 after buying an additional 1,610 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analysts Set New Price Targets

GILD has been the topic of a number of research reports. Piper Sandler raised their price target on Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Leerink Partners upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $74.00 to $96.00 in a research note on Monday, October 21st. Barclays raised their price target on Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 7th. Wolfe Research assumed coverage on Gilead Sciences in a research note on Friday, November 15th. They issued an “outperform” rating and a $110.00 target price on the stock. Finally, Oppenheimer lifted their target price on Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Eleven analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $98.39.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares in the company, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jeffrey Bluestone sold 6,788 shares of the company’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the transaction, the director now owns 8,920 shares of the company’s stock, valued at $815,198.80. The trade was a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 572,824 shares of company stock worth $53,611,715 over the last three months. 0.29% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Up 1.7 %

GILD opened at $99.65 on Thursday. The business’s fifty day moving average is $92.86 and its two-hundred day moving average is $86.41. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The company has a market cap of $124.19 billion, a price-to-earnings ratio of 1,107.22, a PEG ratio of 1.37 and a beta of 0.18. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $100.51.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. The company had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the business earned $2.29 earnings per share. Analysts anticipate that Gilead Sciences, Inc. will post 4.34 EPS for the current fiscal year.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.